Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2024 | Story André Damons | Photo André Damons
Dr Innocensia Mangoato
Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. Here she is with her supervisor and mentor Prof Motlalepula Matsabisa, Director of the University of the Free State (UFS) Department of Pharmacology.

A lecturer and researcher from the University of the Free State (UFS) Department of Pharmacology hopes her research into the use of cannabis in reversing anticancer drug resistance is a step forward into treating various cancers especially in Southern Africa.

Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with the degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. She started her career as a research scientist in the area of African traditional medicines in 2018 and her research received both national and international recognition.

“It’s an amazing (feeling to graduate today). My PhD journey was smooth and beautiful and with mentorship of Prof (Motlalepula) Matsabisa, who groomed me well, I did not shed a tear,” said Dr Mangoato. Dr Gudrun S Ulrich-Merzenich from the University of Bonn in Germany, was her co-supervisor with Prof Matsabisa.

According to the graduation programme, Dr Mangoato, Lecturer and Researcher in the UFS Department of Pharmacology, with her thesis titled Investigating the anticancer and possible resistant reversal effects of cannabis sativa l. extracts in cervical cancer cell lines and modulation of ABC transporters comprehensively explored the therapeutic potential of Cannabis sativa L. in overcoming drug resistance in cervical cancer using in vitro and network pharmacology approaches.

A step forward for treating various cancers

The research looked at the chemical fingerprints and pharmacological targets of C. sativa L. extracts, highlighting its antiproliferative properties against normal non-cancerous cells, cervical cancer cells and the cisplatin-resistant cervical cancer cells. Through PCR analysis, distinct gene expression profiles were identified, revealing the potential effects of combination treatments to counteract cisplatin resistance by downregulating genes associated with drug transporters and crucial signalling pathways. This work provides valuable insights into innovative therapeutic strategies for improving cervical cancer treatment, highlighting new avenues for overcoming resistance and enhancing treatment efficacy though the possible use of plant extracts.

“I hope my research takes a step forward in treating various cancers – especially gynaecology cancers in the Southern Hemisphere in Africa. Hopefully the research can later transcend into clinical trials and hopefully influence more policymakers. We also hope to further develop cannabis to be used as an adjuvant therapy for those drugs that are failing to treat cancer,” says Dr Mangoato, who was the recipient of the Women in Science Master’s Student in 2018.

Her graduation was also a proud moment for Prof Matsabisa, an expert in traditional African medicine, who was like a father to her during her studies. “Prof identified me from my honours degree and walked this journey with me. He has been a great mentor, a father and an amazing supervisor.”

Dr Mangoato says she will for now focus on research only and helping and monitoring upcoming researchers, especially female researchers as there is a scarcity of them her field. 

News Archive

UFS first tertiary institution in SA to form association with the Arbinger Institute
2008-02-15

 

 A two-day seminar entitled: "The Choice and The Choice @ Work" was recently presented in Bloemfontein to companies in the Free State region. Here are, from the left: Mr Braam Botha (Well @ Work), Mr Jozef Myburgh (Telkom), and Dr Cobus Pienaar (from the Department of Industrial Psychology at the UFS and facilitator of the Arbinger Programme).
Photo: Lacea Loader

 

UFS first tertiary institution in SA to form association with the Arbinger Institute

The University of the Free State (UFS) has become the first tertiary institution in the country to form an association with the Arbinger Institute in the United States of America (USA).

“The Arbinger Institute is a global management training and consulting firm applying the implications of self-deception and its solutions to all aspects of organisational performance. Our association with this Institute is a major step for the development of leadership in the country,” says Mr Danie Jacobs, Head of the Centre for Business Dynamics at the UFS.

Dr Cobus Pienaar, from the Department of Industrial Psychology at the UFS, is currently the only licensed facilitator to present Arbinger’s work in South Africa. Dr Pienaar presents The Choice and The Choice @ Work programme on behalf of the Centre for Business Dynamics, under the banner of the UFS School of Business.

According to Mr Jacobs, the programme has already had successes in South Africa. “Dr Pienaar presented the first programme last year in Bloemfontein and Pretoria to leaders from various companies. The feedback on the application of the programme to the South African business environment was phenomenal,” says Mr Jacobs.

The Arbinger Institute’s change work grows out of the scholarly work of philosopher Terry Warner. With an international team of scholars, Warner has broken new ground in solving the age-old problem of self-deception, or what was originally called “resistance”.

“This phenomenon is at the heart of much organisational failure. It is the reason why many organisational problems seem so intractable at their core – they are in self-deception; they resist solution,” says Mr Jacobs.

Media release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
15 February 2008

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept